Information for health-care providers

The following handouts are designed for health-care professionals caring for children or adolescents who will be starting or who are already using atypical antipsychotic medications:

• Brochure: What is the Provincial Mental Health Metabolic Program?
• Metabolic Assessment, Screening & Monitoring Tool
  • 2014 version
  • 2011 version
• Measurement Guide for Metabolic Assessment, Screening & Monitoring Tool
• Referral Criteria for the Provincial Mental Health Metabolic Program
  
• Referral Form to the Provincial Mental Health Metabolic Program
• A Physician Handbook for Metabolic Monitoring for Youth with Mental Illness treated with Second-Generation Antipsychotics
• Treatment Recommendations for Metabolic Complications Associated with Second Generation Antipsychotic (SGA) Use in Children: A Quick Reference Guide

A more complete listing of resources for professionals using second-generation antipsychotic medications in children is available here. More information about how to refer a patient to the Mental Health Metabolic Program is available here.

Information for parents and caregivers

The following handouts are designed to give to families of children or adolescents who will be starting or who are already using atypical antipsychotic medications:

• Family Toolkit
• Patient and Family Guide to Second Generation Antipsychotics
• Antipsychotic Monitoring Form
• Second-Generation Antipsychotics (SGAs), Prolactin, Diet & Activity

A more complete listing of resources for parents and caregivers of children using second-generation antipsychotic medications is available here. More information about the Mental Health Metabolic Program is available here.

The Canadian Alliance for Monitoring Effectiveness and Safety of Antipsychotics in Children (CAMESA) Guideline Project of the Canadian Academy of Child and Adolescent Psychiatry have published guidelines for monitoring for complications and safety of second-generation antipsychotics in chilldren and adolescents in Canada:

• Ho J, Panagiotopoulos C, McCrindle B, Grisaru S, Pringsheim T, for the CAMESA guideline group. Management recommendations for metabolic complications associated with second generation antipsychotic use in children and youth. Journal of the Canadian Academy of Child and Adolescent Psychiatry 2011;20(3):234–241.
  
• Pringsheim T, Panagiotopoulos C, Davidson J, Ho J, for the CAMESA guideline group. Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. Journal of the Canadian Academy of Child and Adolescent Psychiatry 2011;20(3):218–233.